<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909437</url>
  </required_header>
  <id_info>
    <org_study_id>EMICH</org_study_id>
    <nct_id>NCT04909437</nct_id>
  </id_info>
  <brief_title>Efficacy of MYCOBIOTIC® in Children With Stool Culture Positive for Candida sp.</brief_title>
  <acronym>EMICH</acronym>
  <official_title>Efficacy of MYCOBIOTIC® In Children With Stool Culture Positive for Candida sp. Double Blind, Placebo Controlled, Prospective, Cross-over Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nature Science Sp. z o.o.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Network M. Woynarowski, J. Kierkuś Spółka jawna (MED-NET)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nature Science Sp. z o.o.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomised, double blind, placebo controlled, parallel arm,&#xD;
      cross-over, multicentre study conducted in a population of children with stool culture&#xD;
      positive for Candida sp. observed at outpatient primary health care centres.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomised, double blind, placebo controlled, parallel arm, cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reducuction of the rate of patients with stool culture positive for Candida sp.</measure>
    <time_frame>Day 42 +/-6</time_frame>
    <description>assess whether administration of MYCOBIOTIC® reduces the rate of patients with stool culture positive for Candida sp. in children.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MYCOBIOTIC® influence for the intensity of abdominal pain;</measure>
    <time_frame>Day 21+/-3; Day 42+/-3, Day 49 +/-3</time_frame>
    <description>ssess if administration of MYCOBIOTIC® influence the intensity of the abdominal symptoms reported by parents or caregivers - abdominal pain;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MYCOBIOTIC® influence for the intensity of stool frequency and consistency</measure>
    <time_frame>Day 21+/-3; Day 42+/-3, Day 49 +/-3</time_frame>
    <description>assess if administration of MYCOBIOTIC® influence the intensity of the abdominal symptoms reported by parents or caregivers - stool frequency and consistency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MYCOBIOTIC® influence for the intensity of abdominal distention</measure>
    <time_frame>Day 21+/-3; Day 42+/-3, Day 49 +/-3</time_frame>
    <description>assess if administration of MYCOBIOTIC® influence the intensity of the abdominal symptoms reported by parents or caregivers - abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MYCOBIOTIC® influence for the intensity of abdominal bloating</measure>
    <time_frame>Day 21+/-3; Day 42+/-3, Day 49 +/-3</time_frame>
    <description>assess if administration of MYCOBIOTIC® influence the intensity of the abdominal symptoms reported by parents or caregivers - abdominal bloating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MYCOBIOTIC® influence for the intensity of vomiting</measure>
    <time_frame>Day 21+/-3; Day 42+/-3, Day 49 +/-3</time_frame>
    <description>assess if administration of MYCOBIOTIC® influence the intensity of the abdominal symptoms reported by parents or caregivers - vomiting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stool Culture Positive for Candida Species</condition>
  <arm_group>
    <arm_group_label>Mycobiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mycobiotic</intervention_name>
    <description>1 sachet/day, 21 days, oral</description>
    <arm_group_label>Mycobiotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 sachet/day, 21 days, oral</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Boys and girls aged 3-15 years&#xD;
&#xD;
          2. Presence of symptoms suggesting possibility of Candida sp. presence in the stool&#xD;
&#xD;
          3. Informed consent for participation in the study signed by parents/ legal caregivers&#xD;
             and child 13+ years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic intestinal disease, immunodeficiency or immunosuppressive treatment.&#xD;
&#xD;
          2. Chronic or acute diarrheal disease.&#xD;
&#xD;
          3. Use of laxatives or antydiarrhoeal treatment within the week before inclusion in the&#xD;
             study.&#xD;
&#xD;
          4. Antibiotic treatment for the last four weeks before inclusion in the study.&#xD;
&#xD;
          5. Intake of probiotic products for the last two weeks before inclusion in the study&#xD;
&#xD;
          6. Known hypersensitivity to any of the ingredients in the probiotic product or the&#xD;
             placebo (corn starch, magnesium stearate ± bacterial culture).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agnieszka Olek</last_name>
    <phone>+48 504 042 094</phone>
    <email>med-net@med-net.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bożena Kuran</last_name>
    <phone>+48 504 042 094</phone>
    <email>med-net@med-net.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NZOZ Promed</name>
      <address>
        <city>Kielce</city>
        <zip>25-633</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Świętokrzyskie Centrum Pediatrii - Poradnia Gastroenterologiczna dla Dzieci</name>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Świętokrzyskie Centrum Pediatrii</name>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BIMED</name>
      <address>
        <city>Mszczonów</city>
        <zip>96-320</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum dr Ozimek</name>
      <address>
        <city>Warszawa</city>
        <zip>02-765</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stool culture</keyword>
  <keyword>Candida sp.</keyword>
  <keyword>probiotic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

